DR. MARK GOODARZI, M.D.
Osteopathic Medicine in Los Angeles, CA
License number
California A66512
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
8700 Beverly Blvd., Los Angeles, CA 90048
Phone
(310) 423-4774
(310) 423-0440 (Fax)
(310) 423-0440 (Fax)
Personal information
See more information about MARK GOODARZI at radaris.comName
Address
Phone
1418 Butler Ave, Los Angeles, CA 90025
236 N Lucerne Blvd, Los Angeles, CA 90004
1447 Saltair Ave, Los Angeles, CA 90025
1418 Butler Ave, Los Angeles, CA 90025
236 Lucerne Blvd, Los Angeles, CA 90004
Organization information
See more information about MARK GOODARZI at bizstanding.comMark Goodarzi MD,PHD
8700 Beverly Blvd, Los Angeles, CA 90048
Industry:
Endocrinologist, Internist
Phone:
(310) 423-4774 (Phone)
Mark Omid Goodarzi
Professional information
See more information about MARK GOODARZI at trustoria.com
Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance And Coronary Artery Disease
Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance And Coronary Artery Disease
US Patent:
7141373, Nov 28, 2006
Filed:
Jun 16, 2003
Appl. No.:
10/463301
Inventors:
Kent D. Taylor - Ventura CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Willa A. Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie J. Raffel - Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Willa A. Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie J. Raffel - Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/68, C12P 19/34, C07H 21/04
US Classification:
435 6, 435 912, 536 232, 536 235
Abstract:
Disclosed is a method for determining haplotypes useful for large-scale genetic analysis, within a genomic reference sequence of interest, for a human subpopulation. The method can applied to statistically evaluating the genotypes of subjects for any statistically significant association with a phenotype of interest, such as insulin resistance or coronary artery disease. Thus, also disclosed are a method of detecting a genetic predisposition in a Mexican-American human subject for developing insulin resistance and methods of detecting a lower than normal risk in a Mexican-American human subject for developing insulin resistance or coronary artery disease.
Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance, Coronary Artery Disease And Other Phenotypes
Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance, Coronary Artery Disease And Other Phenotypes
US Patent:
8178294, May 15, 2012
Filed:
Nov 28, 2006
Appl. No.:
11/564243
Inventors:
Kent D. Taylor - Ventura CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Hockessin DE, US
Willa A. Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie J. Raffel - Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Hockessin DE, US
Willa A. Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie J. Raffel - Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435 61, 435 912
Abstract:
Disclosed is a method for determining haplotypes useful for large-scale genetic analysis, within a genomic reference sequence of interest, for a human subpopulation. The method can applied to statistically evaluating the genotypes of subjects for any statistically significant association with a phenotype of interest, such as insulin resistance or coronary artery disease. Thus, also disclosed are a method of detecting a genetic predisposition in a human subject for certain biological conditions, which may be related to coronary artery disease.
Dr. Mark O Goodarzi, Los Angeles CA - MD (Doctor of Medicine)
Dr. Mark O Goodarzi, Los Angeles CA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism
Address:
Los Angeles Office
8700 Beverly Blvd, Los Angeles 90048
(800) 233-2771 (Phone), (310) 659-3928 (Fax)
Cedars-Sinai Med Ctr END/RHU
8723 Alden Dr SUITE 298, Los Angeles 90048
(310) 423-3870 (Phone)
8700 Beverly Blvd, Los Angeles 90048
(800) 233-2771 (Phone), (310) 659-3928 (Fax)
Cedars-Sinai Med Ctr END/RHU
8723 Alden Dr SUITE 298, Los Angeles 90048
(310) 423-3870 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 2002, Internal Medicine, 2010
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Education:
Medical School
University of California At San Francisco
Graduated: 1997
U Calif Mc
University Of California-Los Angeles
University of California At San Francisco
Graduated: 1997
U Calif Mc
University Of California-Los Angeles
Mark Omid Goodarzi, West Hollywood CA
Mark Omid Goodarzi, West Hollywood CA
Specialties:
Internist
Address:
8700 Beverly Blvd, West Hollywood, CA 90048
Methods Of Diagnosing Insulin Resistance And Sensitivity
Methods Of Diagnosing Insulin Resistance And Sensitivity
US Patent:
2012008, Apr 12, 2012
Filed:
Oct 30, 2009
Appl. No.:
13/126695
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Xiuqing Guo - Santa Monica CA, US
Mark O. Goodarzi - Los Angeles CA, US
Leslie Raffel - Los Angeles CA, US
Thomas A. Buchanan - Los Angeles CA, US
Anny Xiang - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Xiuqing Guo - Santa Monica CA, US
Mark O. Goodarzi - Los Angeles CA, US
Leslie Raffel - Los Angeles CA, US
Thomas A. Buchanan - Los Angeles CA, US
Anny Xiang - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 612
Abstract:
Methods of diagnosing susceptibility to metabolic insulin resistance and other related conditions are disclosed. The method provides means of diagnosing susceptibility to insulin resistance in Hispanic Americans by determining the presence of a risk haplotype at the LPL locus, the LPIN1 locus, and/or elevated levels of gamma-glutamyl transferase.
Lipoprotein Lipase And Its Effect On Statin Treatments
Lipoprotein Lipase And Its Effect On Statin Treatments
US Patent:
2010013, May 27, 2010
Filed:
Mar 28, 2008
Appl. No.:
12/594143
Inventors:
Mark O. Goodarzi - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Maren T. Scheuner - Manhattan Beach CA, US
Xiuqing Guo - Santa Monica CA, US
Prediman K. Shah - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Maren T. Scheuner - Manhattan Beach CA, US
Xiuqing Guo - Santa Monica CA, US
Prediman K. Shah - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68, A61K 31/366
US Classification:
514460, 435 6
Abstract:
The invention provides methods of treating and prognosing atherosclerosis and lipid response to statin treatment by determining the presence or absence of haplotypes at the lipoprotein lipase locus. In one embodiment, the invention is practiced by evaluating the prognosis of vascular grafts in an individual undergoing statin treatment by determining the presence or absence of haplotypes at the lipoprotein locus.